Ark Invest, led by Cathie Wood, made significant trades on Monday. Among the most prominent was the sale of shares in ...
BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback